Patent No. EP1802302 (titled "Novel Use Of A-Sympathomimetics Having A 2-Imidazoline Structure") was filed by Merck Patent on Sep 16, 2005. The application was issued on Oct 26, 2016.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.